Sökning: onr:"swepub:oai:DiVA.org:liu-45524" >
Cost-effectiveness ...
-
Aspelin, P.Karolinska Institutet
(författare)
Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy
- Artikel/kapitelEngelska2005
Förlag, utgivningsår, omfång ...
-
Elsevier BV,2005
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-45524
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-45524URI
-
https://doi.org/10.1016/j.ahj.2004.07.020DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:1929637URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:for swepub-publicationtype
Anmärkningar
-
Background: Acute renal failure after contrast-induced nephropathy is a clinically important and costly complication after the use of iodine-based contrast media. We investigated the cost and cost-effectiveness of 2 contrast media in patients at high risk of contrast-induced nephropathy. Methods: The analyses were based on a randomized, prospective, multinational clinical study comparing the nephrotoxic effects of an isosmolar nonionic contrast medium, iodixanol, with those of a low-osmolar nonionic contrast medium, iohexol. Resource utilization data were obtained from the study and from a retrospective review of patients' hospital records. Swedish, German, and French unit prices were applied to resources used. Between-group differences in average costs were analyzed using a nonparametric bootstrap method. Results: Resource utilization data for 125 patients were analyzed. Seven contrast media-related serious adverse reactions, of which 6 were acute renal failures, were noted in 6 patients receiving iohexol. Two patients in the iodixanol group had 1 nonserious reaction each. The mean hospitalization cost per patient was €489, €573, and €393 lower after iodixanol than after iohexol using Swedish, German, and French unit prices, respectively. The mean per-patient costs of treating adverse drug reactions were €371, €399, and €445 lower after iodixanol than after iohexol, using the respective unit prices (P = 0.01). Iodixanol was cost-effective compared with iohexol, with both lower costs and better effects related to fewer adverse drug reactions. Conclusions: The isosmolar contrast medium iodixanol appears to be cost-effective when compared with a low-osmolar contrast medium, iohexol, in diabetic patients with renal impairment undergoing angiography. © 2005, Elsevier Inc. All rights reserved.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Aubry, P.Department of Cardiology, Ctr. Hosp. Universitaire Bichat, Paris, France
(författare)
-
Fransson, Sven GöranÖstergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Institutionen för medicin och vård,Kardiologiska kliniken(Swepub:liu)svefr70
(författare)
-
Strasser, R.Department of Cardiology, Heart Center, University of Technology, Dresden, Germany
(författare)
-
Willenbrock, R.Department of Cardiology, Hospital St. Elisabeth, Halle, Germany
(författare)
-
Lundkvist, J.Karolinska Institutet
(författare)
-
Karolinska InstitutetDepartment of Cardiology, Ctr. Hosp. Universitaire Bichat, Paris, France
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:American Heart Journal: Elsevier BV149:2, s. 298-3030002-87031097-6744
Internetlänk
Hitta via bibliotek
Till lärosätets databas